AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.
You may also be interested in...
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.
Sanofi Should Take Note: Insiders Might Just Make Better CEOs
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.